< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 64
- Fat as a villain in Crohn's diseaseFrom1 Mar 2024 → TodayFunding: Foreign private sponsor - undefined
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
Publications
1 - 10 of 1016
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.(2024)
Authors: Séverine Vermeire
Pages: 415 - 427 - Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study(2024)
Authors: Séverine Vermeire, Jeroen Raes, Noël Knops
- Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.(2024)
Authors: Séverine Vermeire
Pages: 403 - 412 - Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.(2024)
Authors: Séverine Vermeire
Pages: 404 - 415 - Crohn's disease.(2024)
Authors: Séverine Vermeire
Pages: 1177 - 1191 - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study(2024)
Authors: Séverine Vermeire
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State(2024)
Authors: Tom Hillary, Maya Imbrechts, Thomas Vanassche, Maria Garmyn, Séverine Vermeire
- Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)